Compare Regeneron Pharmaceuticals Inc (REGN) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Simon Property Group Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Simon Property Group Inc trades at $227.7 (market cap $73.55B). The key difference: Regeneron Pharmaceuticals Inc and Simon Property Group Inc are close in size by market cap, and Simon Property Group Inc pays the higher dividend (3.88%). Which is the better fit depends on your goals.
| REGN | SPG | |
|---|---|---|
Market Cap | $70.79B | $73.55B |
Sector | Health | Real Estate |
52-Week High | $812.27 | $228.70 |
52-Week Low | $545.46 | $160.68 |
Enterprise Value | $64.74B | $102.03B |
Dividend Yield | 0.56% | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SPG trades at $226.79, down 0.84% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 earnings beating expectations at $1.48 per share versus $1.46 expected, continuing a pattern of earnings outperformance. Revenue growth has accelerated from $5.3B in 2022 to $6.4B in 2025, while net income surged to $4.63B with a remarkable 72.7% profit margin. Recent corporate developments include a $2.25 dividend payment and Euro-denominated note offering.
SPG presents a compelling investment case with strong operational performance and dividend yield exceeding 4%, though current valuation metrics suggest limited upside from analyst consensus targets. Key risks include high leverage with $24.21B long-term debt and sensitivity to interest rate movements. The stock's technical overbought condition near resistance levels warrants caution despite positive earnings momentum and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
